European Network against privatization and commercialization of Health and Social protection
You are here : Home » To deepen » Movements & Resistance » Putting People’s Health First: Improving Access to Medicines in (...)

Putting People’s Health First: Improving Access to Medicines in Europe

D 3 December 2018    


agrandir

The European Network against the commercialization and privatization of health and social protection and the Belgian Platform for action on health and solidarity are supporting the European election Manifesto of the European Alliance for Responsible R&D and Affordable Medicines.

Read more about this Manifesto here!

EU investments need to be driven by public health needs and ensure the accessibility, availability and affordability of the R&D results. Open science, including open data and access to publications, should be adopted as standard practice.

Healthy competition and trade

The EU should reform its intellectual property rights (IPR) system ensuring a healthy balance between private interests and the public interest. Competition is crucial to promote innovation: the EU should ensure faire competition by preventing and sanctioning anti-competitive behaviours. Moreover, the EU should refrain from exporting unfair standards of IPR and implement trade policies which support global health.

A sustainable R&D system

The EU and Member States need to foster healthy competition and incentivise real innovation to create a sustainable system for governments and patients. New R&D models based on open science principles should be explored, such as the delinkage of the incentive to develop medicines from the expectation of high prices, innovation inducement prices, socially responsible licensing and open source research, by means of pilot programmes, feasibility studies and new funding schemes.

Real innovative medicines must prove added therapeutic value compared with existing treatments. High standards of scientific evidence for the marketing authorisation of new products must be maintained and promoted. Transparency if clinical trial data and pharmaceutical safety monitoring should be improved. EU cooperation on Healthy Technology Assessment should be strengthened in line with the highest level of transparency, independence, evidence-based decisions and the absence of any conflicts of interest.

Health and R&D policies are critical to the success of the European project. In order to put citizens at the centre of policy-making in this area, the following issues must be prioritized on the agenda of the next European Parliament and the new European Commission:

  • Public return on public investment: taxpayers’ money invested into biomedical R&D should ensure public return and societal benefit. EU investments must be driven by public health needs and ensure the accessibility, availability and affordability of the R&D results. Open science, including open data and access to publications, should be adopted as standard practice.
  • A sustainable R&D system: The EU and Member States need to foster healthy competition and incentivise real innovation to create a sustainable system for governments and patients. New R&D models based on open science principles should be explored, such as the delinkage of the incentive to develop medicines from the expectation of high prices, innovation inducement prizes, socially responsible licensing and open source research, by means of pilot programmes, feasibility studies and new funding schemes.
  • Healthy competition and trade: the EU should reform its intellectual property rights (IPR) system ensuring a healthy balance between private interests and the public interest. Competition is crucial to promote innovation: the EU should ensure fair competition by preventing and sanctioning anti-competitive behaviours. Moreover, the EU should refrain from exporting unfair standards of IPR and implement trade policies which support global health.
  • Real innovation and patients’ safety: New innovative medicines must prove added therapeutic value compared with existing treatments. High standards of scientific evidence for the marketing authorisation of new products must be maintained and promoted. Transparency of clinical trial data and pharmaceutical safety monitoring should be improved. EU cooperation on Health Technology Assessment should be strengthened in line with the highest level of transparency, independence, evidence-based decisions and the absence of any conflicts of interest.

Supporting organizations of the Manifesto

Download the European Elections Manifesto “Putting People’s Health First: Improving Access to Medicines in Europe”

Search

December 2018 :

Nothing for this month

November 2018 | January 2019